Compare Neurocrine Biosciences Inc (NBIX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs GeneDx Holdings Corp — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.1× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and GeneDx Holdings Corp for 19 Days on average.
| NBIX | WGS | |
|---|---|---|
Market Cap | $14.36B | $2.02B |
Volume | 1,237,180 | 734,640 |
Sector | Health | Health |
52-Week High | $185.50 | $167.51 |
52-Week Low | $123.10 | $34.51 |
Typical Hold Time | 23 Days | 19 Days |
Enterprise Value | $14.37B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with technical indicators showing a bearish trend despite strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.85 significantly exceeding expectations of $1.85. Revenue growth remains strong, projected to increase from $2.9B in 2025 to $3.4B in 2026, while net profit margins expanded from 16.73% to 20.91%.
Wall Street maintains strong bullish sentiment with 86% buy ratings and a $204.18 consensus price target, representing 45% upside potential. Key risks include execution challenges with the expanding product portfolio and potential pricing pressure on INGREZZA ahead of 2029 patent considerations. The technical bearish signal contrasts with fundamental strength, creating potential entry opportunities for long-term investors.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
